Ex­pand­ing on in­jectable schiz­o­phre­nia fran­chise, J&J se­cures nod for first twice-year­ly treat­ment

Schiz­o­phre­nia, like any psy­chi­atric con­di­tion, can be no­to­ri­ous­ly dif­fi­cult to treat. But J&J’s Janssen unit is cham­pi­oning a new ap­proval in the in­di­ca­tion Wednes­day, one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER